Junichi Watanabe

Summary

Affiliation: ASKA Pharmaceutical Co
Country: Japan

Publications

  1. ncbi Antitumor activity of TZT-1027 (Soblidotin)
    Junichi Watanabe
    ASKA Pharmaceutical Co, Ltd, R and D Administration, 1604 Shimosakunobe, Kawasaki shi, Kanagawa 213 8522 Takatsu ku, Japan
    Anticancer Res 26:1973-81. 2006
  2. ncbi Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma
    Junichi Watanabe
    ASKA Pharmaceutical Co, Ltd, Research and Development Division, 1604 Shimosakunobe, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    Cancer Sci 97:1410-6. 2006
  3. ncbi Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents
    Junichi Watanabe
    ASKA Pharmaceutical Co, Ltd, Research and Development Division, Takatsu ku, Kawasaki shi, Kanagawa, Japan
    Anticancer Drugs 18:905-11. 2007
  4. ncbi The inhibitory effect of docetaxel and p38 MAPK inhibitor on TZT-1027 (Soblidotin)-induced antivascular activity
    Junichi Watanabe
    ASKA Pharmaceutical Co Ltd, Research and Development Division, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    Anticancer Res 27:3909-18. 2007
  5. ncbi Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells
    Junichi Watanabe
    ASKA Pharmaceutical Co, Ltd, Research and Development Division, 1604 Shimosakunobe, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    In Vivo 21:297-304. 2007
  6. ncbi Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy
    Tsugitaka Natsume
    ASKA Pharmaceutical Co, Ltd, R and D Administration, 1604 Shimosakunobe, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    Cancer Sci 98:598-604. 2007
  7. ncbi A novel method for development of malaria vaccines using full-length cDNA libraries
    Akiko Shibui
    Department of Infectious Immunology, Shinshu University Graduate School of Medicine, Nagano, Japan
    Vaccine 23:4359-66. 2005

Collaborators

Detail Information

Publications7

  1. ncbi Antitumor activity of TZT-1027 (Soblidotin)
    Junichi Watanabe
    ASKA Pharmaceutical Co, Ltd, R and D Administration, 1604 Shimosakunobe, Kawasaki shi, Kanagawa 213 8522 Takatsu ku, Japan
    Anticancer Res 26:1973-81. 2006
    ..TZT-1027 (Soblidotin), a newly synthesized dolastatin 10 derivative that depolymerizes microtubules, has potent antitumor activity...
  2. ncbi Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma
    Junichi Watanabe
    ASKA Pharmaceutical Co, Ltd, Research and Development Division, 1604 Shimosakunobe, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    Cancer Sci 97:1410-6. 2006
    ....
  3. ncbi Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents
    Junichi Watanabe
    ASKA Pharmaceutical Co, Ltd, Research and Development Division, Takatsu ku, Kawasaki shi, Kanagawa, Japan
    Anticancer Drugs 18:905-11. 2007
    ..We believe that these dual activities may make TZT-1027 useful for treating solid tumors...
  4. ncbi The inhibitory effect of docetaxel and p38 MAPK inhibitor on TZT-1027 (Soblidotin)-induced antivascular activity
    Junichi Watanabe
    ASKA Pharmaceutical Co Ltd, Research and Development Division, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    Anticancer Res 27:3909-18. 2007
    ..Our aim was to elucidate the mechanism of TZT-1027-induced antivascular activity by investigating the impact of various inhibitors...
  5. ncbi Antiangiogenic activity of TZT-1027 (soblidotin) on chick chorioallantoic membrane and human umbilical vein endothelial cells
    Junichi Watanabe
    ASKA Pharmaceutical Co, Ltd, Research and Development Division, 1604 Shimosakunobe, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    In Vivo 21:297-304. 2007
    ..In this study, it was investigated whether TZT-1027 has also antiangiogenic activity preventing neovascularization...
  6. ncbi Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy
    Tsugitaka Natsume
    ASKA Pharmaceutical Co, Ltd, R and D Administration, 1604 Shimosakunobe, Takatsu ku, Kawasaki shi, Kanagawa 213 8522, Japan
    Cancer Sci 98:598-604. 2007
    ....
  7. ncbi A novel method for development of malaria vaccines using full-length cDNA libraries
    Akiko Shibui
    Department of Infectious Immunology, Shinshu University Graduate School of Medicine, Nagano, Japan
    Vaccine 23:4359-66. 2005
    ..This approach will not only form the basis for development of malaria vaccines but will also be applicable to other parasites and pathogenic microorganisms...